BofA analyst Tazeen Ahmad raised the firm’s price target on Ascendis Pharma (ASND) to $292 from $262 and keeps a Buy rating on the shares. A physician survey conducted in Q1 continued to highlight bullish long-term signals for the Yorvipath launch, with respondents estimating up to 52% of their patients could be on Yorvipath at peak, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma Issues New Employee Warrants as Part of Long-Term Incentive Program
- Ascendis Pharma Reports Strong Week 52 COACH Trial Data for TransCon CNP and hGH Combo in Achondroplasia
- Ascendis Pharma to Replace ADSs With Direct Ordinary Share Listing on Nasdaq
- Ascendis Pharma to list ordinary shares directly on Nasdaq
- Ascendis Pharma announces new data from COACH trial